Belimumab for the treatment of systemic lupus erythematosus

International Journal of Clinical Rheumatology

Volumn 5, Issue 4, 2010, Pages 407-413

  Goldberg, Avram ^a   Katzap, Elena ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

B cell; B lymphocyte stimulator; belimumab; Benlysta ; lupus; systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; B CELL ACTIVATING FACTOR; BELIMUMAB; BENLYSTA; CD20 ANTIGEN; CD27 ANTIGEN; CD69 ANTIGEN; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; PLACEBO; PREDNISONE; RIBONUCLEOPROTEIN ANTIBODY; SM ANTIBODY; SYNDECAN 1; UNCLASSIFIED DRUG;

ANTIBODY TITER; B LYMPHOCYTE; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPOCOMPLEMENTEMIA; INFECTION; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 77955647231     PISSN: 17584272     EISSN: None     Source Type: Journal    
DOI: 10.2217/ijr.10.32     Document Type: Review

References (23)

1. Chan OT, Madaio MP, Shlomchik MJ: The central and multiple roles of B cells in lupus pathogenesis. Immunol. Rev. 169, 107-121 (1999).
2. Nardelli B, Belvedere O, Roschke V et al.: Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97, 198-204 (2001).
3. Sabahi R, Anolik JH: B cell targeted therapy for SLE. Drugs 66(15), 1933-1948 (2006).
4. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ: A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189, 1639-1648 (1999).
5. Kumagai S, Sredni B, House S, Steinberg A, Green I: Defective regulation of B lymphocyte colony formation in patients with SLE. J. Immunol. 228, 258-262 (1982).
6. Looney RJ, Anolik JH, Campbell D, Felgar RE et al.: B cell depletion as a novel treatment for SLE. Arthritis Rheum. 50, 2580-2589 (2004).
7. Cancro MP: Peripheral B cell maturation: the intersection of selection and homeostasis. Immunol. Rev. 197, 89-101 (2004).
8. Moore PA, Belvedere O, Orr A et al.: BLyS: member of the TNF family and B lymphocyte stimulator. Science 285, 260-263 (1999).
9. Mackay F, Woodcock SA, Lawton P et al.: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190, 1697-1710 (1999).
10. Collins CE, Gavin AL, Migone T-S, Hilbert DM, Nemazee D, Stohl W: B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels Arthritis Res. Ther. 8, R6 (2006).
11. Petri M, Stohl W, Chatham W et al.: Association of plasma B lymphocyte stimulator levels and disease activity in SLE. Arthritis Rheum. 58, 2453-2459 (2008).
12. Baker KP, Edwards B, Main SH et al.: Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48, 3253-3265 (2003).
13. Furie R, Stohl W, Ginzler EM et al.: Safety, pharmacokinetic and pharmacodynamic results of a Phase I single and double dose-escalation study of Lymphostat-B in SLE patients. Arthritis Rheum. 48(9), S377 (2003).
14. Wallace DJ, Lisse J, Stohl W et al.: Belimumab, a fully human monoclonal antibody to BlyS, shows bioactivity and reduces systemic lupus erythematosus disease activity. Ann. Rheum. Dis. 65, 62 (2006).
15. Furie R, Lisse J, Merill JT et al.: Multiple SLE disease activitiy measures in a multi-center Phase II SLE trial demonstrate belimumab improves or stabilizes SLE activity. Ann. Rheum. Dis. 65, 63 (2006).
16. Furie R, Wallace D, Lisse J et al.: Novel combined response endpoint shows that belimumab improves or stabilizes SLE disease activity in a Phase II trial. Lupus 16, 43 (2007).
17. Furie R, Petri M, Weisman MH et al.: Belimumab improved or stabilized SLE disease activity and reduced flare rates during 3 years of therapy. Presented at: The Annual Congress of the European League Against Rheumatism (EULAR 2008). Rome, Italy, 12 June (2008).
18. Chatham W, Stohl W, Merrill JT et al.: LBSL02 study group. Changes in circulating B-cell subtype counts, autoantibody levels and immunoglobulin that associate with therapeutic responsiveness in SLE to BLyS protein antagonism by belimumab. EULAR (2007) (Abstract).
19. Stohl W, Chatham W, Mckay J et al.; LBSL02 Study Group. Progressive normalization of autoantibody, immunoglobulin, and complement levels over 2.5 years of Belimumab therapy in SLE patients. Ann. Rheum. Dis. 56, S210 (2007) (Abstract 426).
20. Merrill JT, Wallace DJ, Stohl W et al.; LBSL02/99 Study Group. Safety profile of belimumab in patients with SLE treated during a placebo controlled trial and in a long term continuation study. Arthritis Rheum. 56, S210 (2007) (Abstract 427).
21. Navarra S, Guzman R, Gallacher A et al.: Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the Phase III BLISS-52 study. Presented at: 73rdAnnual Scientific Meeting of the American College of Rheumatology. PA, USA, 17-21 October 2009.
22. Human genome sciences and glaxosmithkline announce positive results in second of two Phase III trials of BENLYSTA in systemic lupus erythematosus. HGSIPress Release. November, 2009 http://www.hgsi.com/belimumab.html
23. GlaxoSmithKline and Human Genome Sciences announce topline 76-week results of Phase III trial of Benlysta™ in systemic lupus erythematosus. GSKand HGS Press Release. 20 April, 2010 http://www.gsk.com/media/pressreleases/ 2010/2010-pressrelease-10039.htm